Osiris Therapeutics Inc (OSIR.OQ)
27 Oct 2016
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||Chairman of the Board|
|68||2016||Interim President and Chief Executive Officer|
|49||2015||Chief Financial Officer, Corporate Secretary and Treasurer|
|46||2014||Vice President, General Manager of Wound Care|
- BRIEF-Osiris Therapeutics says commenced steps to terminate enrollment in OTI-15-01 phase III clinical trial
- BRIEF-Osiris says provides update regarding Nasdaq listing matters
- BRIEF-Osiris Therapeutics files for non-timely 10-Q with U.S. SEC - SEC filing
- BRIEF-Mimedx Group files lawsuit against Osiris for false and misleading representations
- BRIEF-Osiris provides update regarding Nasdaq listing matters